BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, April 3, 2026
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
May 22, 2002
View Archived Issues
European Parliament Endorses Part Of Biotech Spending Plan
Read More
Rational Drug Discovery Approach Looks Promising For Alzheimer's
Read More
Genome Express Offers Bacterial Genomics Sequencing Service
Read More
Speedel Moves SPP 301 Into Phase II Pilot Studies
Read More
Celltech Picks Amgen To Help Advance Osteoporosis Program
Read More
HGS Gets Exclusive Development Rights To CAT Cancer Antibody
Read More
CeNeS Releases Positive Interim Results Of CNS5161 In Phase II
Read More
Enact Acquires Rights To Cytoxic, Prepares To File For Approvals
Read More
Other News To Note
Read More
Genset Chairman Resigns, Is Succeeded By Vasseur
Read More
Australian States Compete In Separate Biotech Initiatives
Read More
IDM Receives Approval For Ovarian Cancer Therapy Trial
Read More
Ark Delays Initial Public Offering Due To Unfavorable Conditions
LONDON - Ark Therapeutics Group plc postponed its initial public offering on the London Stock Market, blaming "unusually adverse market conditions." (BioWorld International)
Read More
